NCT03240809View on ClinicalTrials.gov

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Psoriasis
Interventions
BIOLOGICAL

Brodalumab

140 mg SC dose

BIOLOGICAL

Brodalumab

70 mg SC dose

Trial Locations (5)

33155

Bausch Site 002, Miami

Bausch Site 004, Miami

45242

Bausch Site 001, Las Vegas

89052

Bausch Site 005, Henderson

92123

Bausch Site 003, San Diego

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY